Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management

Chiara Casadei, Giuseppe Schepisi, Cecilia Menna, Michal Chovanec, Giorgia Gurioli, Valentina Gallà, Amelia Altavilla, Massimo Marcellini, Salvatore Roberto Bellia, Cristian Lolli, Michal Mego, Giovanni Rosti, Ugo De Giorgi

Research output: Contribution to journalArticle

Abstract

Germ cell tumors represent 11% of the cancers diagnosed in adolescent males and are the most common solid tumors in adult men between the ages of 20 and 35. Pure seminoma accounts for around 50% of all testicular germ cell tumors. The prognostic classification of the International Germ Cell Cancer Collaborative Group for good-prognosis seminoma includes both nodal disease and pulmonary visceral metastases. In this article, we analyzed recent data on prognosis and outcome of good-prognosis seminoma to revise the traditional classification of the disease and improve tailored treatment.

Original languageEnglish
Pages (from-to)1347-1352
Number of pages6
JournalFuture Oncology
Volume15
Issue number12
DOIs
Publication statusPublished - Apr 1 2019

    Fingerprint

Keywords

  • biomarkers
  • bleomycin
  • chemotherapy
  • germ cell tumors
  • high-dose
  • human chorionic gonadotropin
  • metastases
  • platinum
  • prognosis
  • seminoma
  • α-fetoprotein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Casadei, C., Schepisi, G., Menna, C., Chovanec, M., Gurioli, G., Gallà, V., Altavilla, A., Marcellini, M., Bellia, S. R., Lolli, C., Mego, M., Rosti, G., & De Giorgi, U. (2019). Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management. Future Oncology, 15(12), 1347-1352. https://doi.org/10.2217/fon-2018-0850